Beroctocog alfa

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Beroctocog alfa
Accession Number
DB14473
Type
Biotech
Groups
Approved, Investigational
Biologic Classification
Protein Based Therapies
Blood factors
Description
Not Available
Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
  • Factor VIII
  • Human antihemophilic factor/von willebrand factor complex
  • Human coagulation factor VIII/von willebrand factor complex
  • Octanate
Active Moieties
NameKindUNIICASInChI Key
Antihemophilic factor humanunknown839MOZ74GKNot AvailableNot applicable
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AlphanateKit2000 [iU]/10mLIntravenousGRIFOLS USA, LLC2007-01-31Not applicableUs
AlphanateKit250 [iU]/5mLIntravenousGRIFOLS USA, LLC2007-01-31Not applicableUs
AlphanateKit2000 [iU]/10mLIntravenousGRIFOLS USA, LLC2007-01-31Not applicableUs
AlphanateKit1500 [iU]/10mLIntravenousGRIFOLS USA, LLC2007-01-31Not applicableUs
AlphanateKit1500 [iU]/10mLIntravenousGRIFOLS USA, LLC2007-01-31Not applicableUs
AlphanateKit1000 [iU]/10mLIntravenousGRIFOLS USA, LLC2007-01-31Not applicableUs
AlphanateKit1000 [iU]/10mLIntravenousGRIFOLS USA, LLC2007-01-31Not applicableUs
AlphanateKit500 [iU]/5mLIntravenousGRIFOLS USA, LLC2007-01-31Not applicableUs
AlphanateKit250 [iU]/5mLIntravenousGRIFOLS USA, LLC2007-01-31Not applicableUs
AlphanateKit500 [iU]/5mLIntravenousGRIFOLS USA, LLC2007-01-31Not applicableUs
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Categories
UNII
5T6B772R4Q
CAS number
9001-27-8

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
(R)-warfarinThe therapeutic efficacy of Beroctocog alfa can be decreased when used in combination with (R)-warfarin.
(S)-WarfarinThe therapeutic efficacy of Beroctocog alfa can be decreased when used in combination with (S)-Warfarin.
4-hydroxycoumarinThe therapeutic efficacy of Beroctocog alfa can be decreased when used in combination with 4-hydroxycoumarin.
AbciximabThe therapeutic efficacy of Beroctocog alfa can be decreased when used in combination with Abciximab.
AcenocoumarolThe therapeutic efficacy of Beroctocog alfa can be decreased when used in combination with Acenocoumarol.
Acetylsalicylic acidThe therapeutic efficacy of Beroctocog alfa can be decreased when used in combination with Acetylsalicylic acid.
Alpha-1-proteinase inhibitorAlpha-1-proteinase inhibitor may increase the thrombogenic activities of Beroctocog alfa.
AlteplaseThe therapeutic efficacy of Beroctocog alfa can be decreased when used in combination with Alteplase.
AmediplaseThe therapeutic efficacy of Beroctocog alfa can be decreased when used in combination with Amediplase.
Aminocaproic acidThe risk or severity of adverse effects can be increased when Aminocaproic acid is combined with Beroctocog alfa.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentCongenital Hematological Disorder / Hemophilia A1
1CompletedTreatmentHemophilia A1
1CompletedTreatmentSevere Hemophilia A1
1RecruitingPreventionHemophilia A1
1, 2RecruitingPreventionHemophilia A1
2CompletedTreatmentHemophilia A1
2RecruitingTreatmentHemophilia A, Congenital1
2, 3CompletedPreventionHemophilia A1
2, 3CompletedTreatmentHemophilia A1
3CompletedDiagnosticHemophilia A1
3CompletedPreventionHemophilia A2
3CompletedPreventionSevere Hemophilia A1
3CompletedTreatmentCongenital Hemophilia A1
3CompletedTreatmentHemophilia A2
3CompletedTreatmentSevere Hemophilia A2
3Not Yet RecruitingTreatmentVon Willebrand Diseases1
3RecruitingTreatmentHemophilia A2
3RecruitingTreatmentHemophilia A / Hereditary factor IX deficiency1
3TerminatedTreatmentSevere Hemophilia A1
3Unknown StatusTreatmentHemophilia A1
4Active Not RecruitingTreatmentSevere Hemophilia A1
4Active Not RecruitingTreatmentVon Willebrand 's disease Type 11
4CompletedBasic ScienceHemophilia A1
4CompletedTreatmentBlood Platelet Disorders / Disorders, Blood Coagulation / Hematologic Diseases / Von Willebrand 's disease Type 11
4CompletedTreatmentCongenital Hematological Disorder / Haemophilia A With Inhibitors / Haemophilia B With Inhibitors1
4CompletedTreatmentSevere Haemophilia A1
4RecruitingTreatmentHemophilia A With Inhibitors1
Not AvailableActive Not RecruitingNot AvailableHemophilia A1
Not AvailableActive Not RecruitingPreventionSevere Hemophilia A1
Not AvailableActive Not RecruitingTreatmentSevere Hemophilia A1
Not AvailableCompletedNot AvailableHemophilia A1
Not AvailableNo Longer AvailableNot AvailableAcquired Hemophilia A1
Not AvailableNot Yet RecruitingNot AvailableHemophilia A1
Not AvailableRecruitingNot AvailableFactor IX Deficiency / Factor VIII Deficiency1
Not AvailableRecruitingNot AvailableHemophilia A2
Not AvailableRecruitingNot AvailableVon Willebrand Diseases1
Not AvailableTerminatedTreatmentHemophilia A With Inhibitors1
Not AvailableWithdrawnNot AvailableJoint Disease1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
KitIntravenous1000 [iU]/10mL
KitIntravenous1500 [iU]/10mL
KitIntravenous2000 [iU]/10mL
KitIntravenous250 [iU]/5mL
KitIntravenous500 [iU]/5mL
KitIntravenous80 [iU]/1mL
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on July 05, 2018 16:41 / Updated on December 02, 2019 10:12